Since there are few pre-clinical IBC models available to study the effects of the small molecule cMET/ALK inhibitor Crizotinib, we developed an ALK+ pre-clinical model of IBC using tumor cells freshly isolated from IBC patient with disease progression evidenced by pleural effusion. Here, ALK is linked to inflammatory breast carcinoma.